N
RARE icon

Natixis’s Ultragenyx Pharmaceutical RARE Stock Holding History

Natixis’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-81,754
Closed -$1.71M – 1340
2026
Q1 		$1.71M Buy
+81,754
New +$1.84M 0.01% 599
2024
Q4 		– Sell
-15,671
Closed -$871K – 1165
2024
Q3 		$871K Buy
+15,671
New +$798K ﹤0.01% 549
2023
Q4 		– Sell
-33,100
Closed -$1.18M – 1151
2023
Q3 		$1.18M Sell
33,100
-31,600
-49% -$1.25M 0.01% 479
2023
Q2 		$2.98M Buy
+64,700
New +$3M 0.02% 364
2022
Q1 		– Sell
-15,863
Closed -$1.33M – 1295
2021
Q4 		$1.33M Sell
15,863
-20,143
-56% -$1.64M ﹤0.01% 868
2021
Q3 		$3.25M Buy
+36,006
New +$3.25M 0.01% 638
2021
Q2 		– Sell
-2,618
Closed -$298K – 945
2021
Q1 		$298K Sell
2,618
-162
-6% -$22.1K ﹤0.01% 1000
2020
Q4 		$385K Buy
+2,780
New +$330K ﹤0.01% 929

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Natixis's RARE Position: Q2 2026 in Review

Natixis sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 81,754 shares — an estimated $1.71M sold.

Natixis first reported a position in RARE in Q4 2020 and held it in 8 quarters. The position peaked at $3.25M in Q3 2021. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Natixis reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 81,754 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.71M.
  • Natixis first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 8 quarters.
  • Natixis's Ultragenyx Pharmaceutical position peaked at $3.25M in Q3 2021.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.